Contineum Therapeutics Q3 net loss widens 46% to $18.7 million
CTNM•Contineum Therapeutics’ third-quarter 2026 net loss widened 46% year over year to $18.7 million, while cash, cash equivalents and marketable securities totaled $244.5 million, supporting projected operations through mid-2029.
1. Quarterly results and cash
Contineum Therapeutics reported a third-quarter 2026 net loss of $18.7 million, up 46% year over year. Research and development expenses rose 45% to $16 million, driven by higher PIPE-791 IPF program expenses and employee-related costs. At September 30, cash, cash equivalents and marketable securities totaled $244.5 million, supporting projected operations through mid-2029. The Phase 2 PROPEL-IPF trial expanded to more than 100 sites across 16 countries to support enrollment.
